Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 12, 2024

Lenvatinib Plus Pembrolizumab vs Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
J. Clin. Oncol 2024 Jan 16;[EPub Ahead of Print], RJ Motzer, C Porta, M Eto, T Powles, V Grünwald, TE Hutson, B Alekseev, SY Rha, J Merchan, JC Goh, AA Lalani, U De Giorgi, B Melichar, SH Hong, H Gurney, MJ Méndez-Vidal, E Kopyltsov, S Tjulandin, TA Gordoa, V Kozlov, A Alyasova, E Winquist, P Maroto, M Kim, A Peer, G Procopio, T Takagi, S Wong, J Bedke, M Schmidinger, K Rodriguez-Lopez, J Burgents, C He, CE Okpara, J McKenzie, TK Choueiri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading